Novartis has nixed six early-stage pipeline programs, swapping in two new phase 1 cancer candidates as replacements. | ...

Amgen’s bad luck in lupus may finally be coming to an end. Daxdilimab, a monoclonal antibody acquired from Horizon ...

Stem cell therapy biotech PrimeGen US is taking the less-traveled special purpose acquisition company (SPAC) route to the ...

Beyond an oral version of its blockbuster weight loss drug Wegovy, which launched last month, Novo touted potential next-gen ...

Just weeks after announcing it would "step up" its acquisitions this year, Medtronic said it will shell out up to ...

Abbott has been hit with a slew of complaints from the FDA in a warning letter related to its continuous glucose monitor (CGM ...

England’s National Health Service’s faecal immunochemical test (FIT) has reduced referrals for suspected bowel cancer by ...

As Eli Lilly awaits an FDA approval decision for its oral GLP-1 orforglipron, the pharma has discarded three clinical-stage drugs, including a gene therapy from its $1 billion acquisition of Prevail ...

Telehealth company Hims & Hers has added Grail’s blood cancer test Galleri to its offerings as the medtech continues to gather up trial data for a potential FDA approval next year.  | Telehealth ...

While interested in CAR-T therapies’ potential to achieve durable, drug-free remission in serious autoimmune conditions, the ...

Luke Miels had only been at the helm of GSK for 20 days before he signed off on his first multibillion-dollar buyout, and the CEO is clear on what else will attract his interest. | Luke Miels had only ...

As the Trump administration continues to pivot away from vaccinations, it is pushing for the development of new antiviral ...